Mitochondria, organelles vital for cellular energy homeostasis as well as being central purveyors of cell death, have recently come into focus as promising targets for anti-cancer therapies (1) (2) (3) . Mitocans are small compounds that exhibit anti-cancer activity by selectively inducing apoptosis by mitochondrial interference, comprising 7 classes of agents with different modes of action (4) . The class 5 mitocans include drugs that act by targeting the mitochondrial electron transport chain (ETC), of which the prime examples are vitamin E (VE) analogs, epitomized by the ester α-tocopheryl succinate (α-TOS) (5, 6), 3- bromopyruvate (3BP) (7) , and adaphostine (8) . VE analogs also belong to the class 2 mitocans since, in addition to targeting the ETC, these agents act as Bcl-2 homology-3 (BH3) mimetics (9) .
VE analogs hold substantial promise as selective anti-cancer drugs since they suppress tumor growth in several pre-clinical models, including mice with experimental breast (10, 11) , lung (12) , prostate (13) and colon carcinomas (6, 14) , as well as mesotheliomas (15, 16) . Due to its selectivity for cancer cells and low toxicity for non-malignant cells (5) , the ester analog α-TOS is an agent that has considerable clinical potential. A similar level of anti-cancer efficacy and selectivity has also been reported for the ether analog of VE α-tocopheryloxyacetic acid (α-TEA) (17, 18) .
The importance of mitochondria as target by which α-TOS induces apoptosis was proposed earlier (19) (20) (21) (22) . Although it is now established that the VE analog causes mitochondrial destabilization through the formation of Bax/Bak channels resulting in cytochrome c translocation and caspase activation (20) (21) (22) , the precise molecular target for apoptosis induction by the agent was not fully understood. α-TOS has been recently identified as a compound that induces apoptosis by targeting the ubiquinone (UbQ)-binding sites in the mitochondrial complex II (CII; succinate dehydrogenase, SDH) (23) . In this respect, we recently reported that the VE analog induces apoptosis by a novel mechanism via generation Dong et al.: Complex II as a new cancer therapy target 5 of reactive oxygen species (ROS) upon displacing UbQ from the membrane subunits of CII (23) . Therefore, electrons that are generated during the conversion of succinate to fumarate by subunit A of CII (SDHA, within the matrix part of the complex; 24) diffuse from CII and reduce molecular oxygen to generate ROS (23, 25 ) that, in turn, induce apoptosis (21, 26, 27) .
In this communication, we show the importance of CII as the major target for the mitocan, α-TOS, using a mouse model with genetically modified tumors expressing either wild type, defective or reconstituted CII. This study highlights the importance of CII as a target for anticancer drugs as well as its essential role in the activity of the mitocan, α-TOS, for promoting apoptosis. SDHC-mutant B9 Ras cells were reconstituted by transfection with a vector encoding a functional human (h) SDHC gene. First, the pEFIRES-P-SDHC plasmid was constructed.
Materials and methods

Cell
SDHC was digested from pCR3.1-SDHC (31) using Nhe1 and Not1. SDHC and pEFIRES-P (32) were separately extracted from the gel using the QIAEX II kit (Qiagen). SDHC was then inserted into pEFIRES-P and the resulting pEFIRES-P-SDHC digested with BamHI to confirm the correct orientation of the cloned SDHC. The construct was amplified and purified using the QIAfilter plasmid purification kit. B9 Ras cells were then reconstituted with hSDHC by transfection with pEFIRES-P-SDHC. G418 (100 μg/ml) and puromycin (4 μg/ml) were used for double selection; single clones were obtained by limiting dilution. Clone 5 of B9 Ras-SDHC cells with high SDHC and H-Ras-EGFP expression was chosen for further studies.
For treatment, cells were grown to ~60% confluency before exposure to α-TOS or thenoyltrifluoroacetone (TTFA) (both Sigma). In some experiments, cells were pre-treated with MitoQ (33, 34) .
Colony-forming assay. The colony-forming activity of the non-transformed B1, B9 and B9 SDHC cells and their H-Ras-transformed counterparts was assessed as described (35) . The number of colonies >50 μm in diameter in each dish was then counted using light microscopy. Sigma) (21, 23) or by flow cytometry using the redox-sensitive probe dihydroethidium (DHE) (21) . MTT and SDH activity analysis. The MTT viability assay was used to assess the proliferative activity of the parental and H-Ras-transformed B1, B9, B10 and B9 SDHC cell lines.
SDH activity was measured using a short term (2 h) modified MTT assay with succinate as the sole source of electrons, driving the respiratory system specifically via CII, as described (11, 23) . to the parental cells (Fig. 2C) . Importantly, the SDHC-mutant B9 Ras cells maintained significantly lower levels of SDH enzymatic activity than the B1 Ras , B10 Ras and B9 Ras-SDHC cells (Fig. 2D ).
We next tested the selected clones of B1 Ras , B9 Ras and B9 Ras-SDHC cells, as well as B10 Ras cells for their response to α-TOS and to the CII inhibitor, TTFA (24) . The data ( Fig. 3A TOS was further documented by EPR spectroscopy analysis (Fig. 3C) , providing similar results to those obtained from using fluorescent probes and flow cytometry for ROS measurement. The specificity of the drug, α-TOS, targeting CII but not CI was confirmed in other studies using rotenone to inhibit CI (data not shown). No significant differences in ROS production by cells treated with α-TOS were detected, even at high (~300 μM) levels, and comparing with or without rotenone inhibition. Hence, the data is entirely consistent with α-TOS targeting CII, but not CI in tumor cell mitochondria.
After establishing that the Ras-transformed cells with defective CII were less responsive to the drug, we proceeded to address whether CII would also be critical as a target for the anti- Hence, the pattern of SDHC mRNA expression in the different types of tumors matched the same distribution in the cell lines from which the tumors were derived (Fig. 4C ).
Since the different types of tumors maintained the characteristics of the source cells, we next assessed the effect of the VE analog on tumors with fully functional, dysfunctional or reconstituted CII. Fig. 5 reveals that B1 Ras and B9 Ras-SDHC cell-derived tumors were highly responsive to α-TOS, whereas the B9 Ras cell-derived tumors were relatively resistant to the same dose of the VE analog. This was also consistent with the reduced apoptotic index revealed by DAPI-staining nuclei in sections from α-TOS-treated mice with B9 Ras cellderived tumors (cf. Fig. 4) . Thus, the results consistently supported the importance of CII as a target for the effectiveness of the mitocan, α-TOS, as an anticancer drug working in vivo.
Discussion
Mitochondria have emerged as attractive targets for anti-cancer drugs (1-3, 38). We have recently proposed to classify these drugs by the term mitocans, referring to small molecules with anti-cancer activity that target mitochondria and induce apoptosis (4, 25, (39) (40) (41) . VE analogs, selectively inducing apoptosis in cancer cells (5) , initiate the cascade of reactions that stimulate ROS accumulation and that culminates in cancer cell death (11, 21, 23) . We have placed VE analogs into group 5 of mitocans, since they act by targeting the mitochondrial ETC (11, 23), similar to 3BP, adaphostin or tamoxifen. Of these mitocans, VE analogs, such as α-TOS and α-TEA, and 3BP affect CII of the ETC (7, 11, 23) , while adaphostin acts at the level of CIII (8) were more resistant to the VE analog. These data document for the first time the importance of CII as a target for anti-cancer drugs in vivo, as exemplified by the vitamin E analog, α-TOS. The importance of CII as a target for α-TOS was further supported by the finding that the VE analog acts mainly at the level of CII, only marginally at CI requiring much higher concentrations of the agent, and does not target CIII, as documented by the O 2 consumption assays using mitochondria isolated from hepatocarcinoma (data not shown).
The CII subunits SDHB, SDHC and SDHD have been proposed as tumor suppressors in several types of neoplastic diseases, including pheochromocytoma and paraganglioma (51) (52) (53) (54) and, rarely, renal cell carcinoma (52, 54) . With respect to highly widespread cancers, it has been shown that one in one million breast cancers features a CII mutation (54) 
